Ryan Savitz, Executive Vice President, Chief Financial Officer, and Chief Business Officer of Dianthus Therapeutics, Inc. /DE/ (DNTH), executed a significant sale of company shares on April 1, 2026. Savitz sold 59,800 shares at an average price of $83.90 per share, realizing approximately $5.02 million.
This transaction adds to a series of sales by Savitz within a close timeframe. On March 31, 2026, filings indicate multiple sales totaling an additional 101,786 shares, amounting to over $7.44 million.
Insider sales can be motivated by a variety of personal financial considerations, such as portfolio diversification or tax planning, and do not necessarily signal a negative view of the company's future prospects.